DRTS Stock Analysis: Buy, Sell, or Hold?
DRTS - Alpha Tau Medical Ltd. Ordinary Shares
$10.58
1.65 (18.48%)
▲
5d:
+2.82%
30d:
+40.5%
90d:
+50.71%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 6.2/10
Get Alerted When DRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
11 traders called DRTS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DRTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DRTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DRTS is currently trading at $10.58, which is considered slightly high relative to its 30-day fair value range of $8.08 to $10.63.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $8.86, while resistance sits at $11.62. The stock is showing strong short-term momentum, up 18.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.80 (+30.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $8.86, while resistance sits at $11.62. The stock is showing strong short-term momentum, up 18.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.80 (+30.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.08 -
$10.63
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+18.5%)
- BULLISH: Trading 30.4% below Wall St target ($13.80)
Trading Range Analysis
30-Day Trading Range
$8.08 -
$10.63
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.86
Resistance Level
$11.62
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.22
Wall Street Target
$13.80
(+30.4%)
Share & Embed Analysis
Last updated: June 03, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
